BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 32142890)

  • 1. Fatostatin inhibits the development of endometrial carcinoma in endometrial carcinoma cells and a xenograft model by targeting lipid metabolism.
    Yao L; Chen S; Li W
    Arch Biochem Biophys; 2020 May; 684():108327. PubMed ID: 32142890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fatostatin displays high antitumor activity in prostate cancer by blocking SREBP-regulated metabolic pathways and androgen receptor signaling.
    Li X; Chen YT; Hu P; Huang WC
    Mol Cancer Ther; 2014 Apr; 13(4):855-66. PubMed ID: 24493696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fatostatin suppresses growth and enhances apoptosis by blocking SREBP-regulated metabolic pathways in endometrial carcinoma.
    Gao S; Shi Z; Li X; Li W; Wang Y; Liu Z; Jiang J
    Oncol Rep; 2018 Apr; 39(4):1919-1929. PubMed ID: 29436682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disruption of Cancer Metabolic SREBP1/miR-142-5p Suppresses Epithelial-Mesenchymal Transition and Stemness in Esophageal Carcinoma.
    Huang CM; Huang CS; Hsu TN; Huang MS; Fong IH; Lee WH; Liu SC
    Cells; 2019 Dec; 9(1):. PubMed ID: 31861383
    [No Abstract]   [Full Text] [Related]  

  • 5. Fatostatin in Combination with Tamoxifen Induces Synergistic Inhibition in ER-Positive Breast Cancer.
    Liu Y; Zhang N; Zhang H; Wang L; Duan Y; Wang X; Chen T; Liang Y; Li Y; Song X; Li C; Han D; Chen B; Zhao W; Yang Q
    Drug Des Devel Ther; 2020; 14():3535-3545. PubMed ID: 32921987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fatostatin Inhibits Cancer Cell Proliferation by Affecting Mitotic Microtubule Spindle Assembly and Cell Division.
    Gholkar AA; Cheung K; Williams KJ; Lo YC; Hamideh SA; Nnebe C; Khuu C; Bensinger SJ; Torres JZ
    J Biol Chem; 2016 Aug; 291(33):17001-8. PubMed ID: 27378817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fatostatin blocks ER exit of SCAP but inhibits cell growth in a SCAP-independent manner.
    Shao W; Machamer CE; Espenshade PJ
    J Lipid Res; 2016 Aug; 57(8):1564-73. PubMed ID: 27324795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations.
    Li X; Wu JB; Chung LW; Huang WC
    Oncotarget; 2015 Dec; 6(38):41018-32. PubMed ID: 26512780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fatostatin reverses progesterone resistance by inhibiting the SREBP1-NF-κB pathway in endometrial carcinoma.
    Ma X; Zhao T; Yan H; Guo K; Liu Z; Wei L; Lu W; Qiu C; Jiang J
    Cell Death Dis; 2021 May; 12(6):544. PubMed ID: 34039951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor effect of XCT790, an ERRα inverse agonist, on ERα-negative endometrial cancer cells.
    Kokabu T; Mori T; Matsushima H; Yoriki K; Kataoka H; Tarumi Y; Kitawaki J
    Cell Oncol (Dordr); 2019 Apr; 42(2):223-235. PubMed ID: 30706380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of sterol regulatory element-binding protein 1 (SREBP1)-mediated lipogenesis by the Epstein-Barr virus-encoded latent membrane protein 1 (LMP1) promotes cell proliferation and progression of nasopharyngeal carcinoma.
    Lo AK; Lung RW; Dawson CW; Young LS; Ko CW; Yeung WW; Kang W; To KF; Lo KW
    J Pathol; 2018 Oct; 246(2):180-190. PubMed ID: 29968360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The antitumor effect of lobaplatin against Ishikawa endometrial cancer cells in vitro and in vivo.
    He J; Zhang H
    Biomed Pharmacother; 2019 Jun; 114():108762. PubMed ID: 30925454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Silibinin inhibits endometrial carcinoma via blocking pathways of STAT3 activation and SREBP1-mediated lipid accumulation.
    Shi Z; Zhou Q; Gao S; Li W; Li X; Liu Z; Jin P; Jiang J
    Life Sci; 2019 Jan; 217():70-80. PubMed ID: 30452972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth Hormone differentially modulates chemoresistance in human endometrial adenocarcinoma cell lines.
    Gentilin E; Minoia M; Bondanelli M; Tagliati F; Degli Uberti EC; Zatelli MC
    Endocrine; 2017 Jun; 56(3):621-632. PubMed ID: 27585662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Curcumin exhibits anti-tumor effect and attenuates cellular migration via Slit-2 mediated down-regulation of SDF-1 and CXCR4 in endometrial adenocarcinoma cells.
    Sirohi VK; Popli P; Sankhwar P; Kaushal JB; Gupta K; Manohar M; Dwivedi A
    J Nutr Biochem; 2017 Jun; 44():60-70. PubMed ID: 28402926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fatostatin promotes anti-tumor immunity by reducing SREBP2 mediated cholesterol metabolism in tumor-infiltrating T lymphocytes.
    Zhu L; Shi Y; Feng Z; Yuan D; Guo S; Wang Y; Shen H; Li Y; Yan F; Wang Y
    Eur J Pharmacol; 2024 May; 971():176519. PubMed ID: 38522641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SREBP inhibition ameliorates renal injury after unilateral ureteral obstruction.
    Mustafa M; Wang TN; Chen X; Gao B; Krepinsky JC
    Am J Physiol Renal Physiol; 2016 Sep; 311(3):F614-25. PubMed ID: 27385736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Propofol inhibits proliferation, migration, and invasion but promotes apoptosis by regulation of Sox4 in endometrial cancer cells.
    Du Q; Liu J; Zhang X; Zhang X; Zhu H; Wei M; Wang S
    Braz J Med Biol Res; 2018; 51(4):e6803. PubMed ID: 29490000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL-24 inhibits endometrial cancer cell proliferation by promoting apoptosis through the mitochondrial intrinsic signaling pathway.
    Liao S; Yang Y; Chen S; Bi Y; Huang Q; Wei Z; Qin A; Liu B
    Biomed Pharmacother; 2020 Apr; 124():109831. PubMed ID: 31972354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of a novel HDAC inhibitor OBP-801/YM753 and a PI3K inhibitor LY294002 synergistically induces apoptosis in human endometrial carcinoma cells due to increase of Bim with accumulation of ROS.
    Yoshioka T; Yogosawa S; Yamada T; Kitawaki J; Sakai T
    Gynecol Oncol; 2013 May; 129(2):425-32. PubMed ID: 23403163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.